国产替加环素治疗泛耐药鲍曼不动杆菌肺炎的临床疗效被引量：3

下载PDF

导出

摘要目的:探讨国产替加环素治疗泛耐药鲍曼不动杆菌(extensively drug resistant A.baumannii,XDRAB)肺炎的临床疗效。方法:选择XDRAB肺炎患者21例,采用国产替加环素治疗,观察治疗效果。结果:治疗后,患者的临床症状得到改善(P<0.05);白细胞计数及中性粒细胞比值、C-反应蛋白、降钙素原(procalcitonin,PCT)等炎症指标以及急性生理与慢性健康评分Ⅱ(acute physiology and chronic health evaluationⅡ,APACHEⅡ)均有所下降(P<0.05)。21例患者中病原菌清除者13例,清除率为61.9%;治疗总有效率71.4%;28 d存活率85.7%。结论:国产替加环素对XDRAB肺炎具有较好的临床疗效,可结合实际情况选择性应用。

作者蒋明彦刘国平刘中华贺志文

机构地区湘潭市中心医院呼吸与危重症医学科

出处《包头医学院学报》 CAS 2016年第10期26-28,共3页 Journal of Baotou Medical College

关键词替加环素泛耐药鲍曼不动杆菌

分类号 R563.1 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献5

1Dominik S, Cezarina M, Alan S, et al. Risk Factors for heahhcare- associated extensively drug- resistant acineto- bacter baumannii infections : a case - control study [ J ]. Plos One ,2014,9 ( 1 ) : e85973 - e85973.
2胡付品,朱德妹,汪复,蒋晓飞,徐英春,张小江,张朝霞,季萍,谢轶,康梅,王传清,王爱敏,徐元宏,沈继录,孙自镛,陈中举,倪语星,孙景勇,褚云卓,田素飞,胡志东,李金,俞云松,林洁,单斌,杜艳,韩艳秋,郭素芳,魏莲花,吴玲,张泓,孔菁,胡云建,艾效曼,卓超,苏丹虹.2014年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2015,15(5):401-410. 被引量：727
3Nwadike VU, Ojide CK, Kalu EI. Muhidrug resistant acineto- bacter infection and their antimicrobial susceptibility pattern in a nigerian tertiary hospital ICU [ J ]. Afr J Infect Dis, 2014,8( 1 ) :14 - 18.
4Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline - based versus colistin - based therapy for treat- ment of pneumonia caused by muhidrug - resistant Acineto- bacter baumannii in a critical setting: a matched cohort a- nalysis [ J ]. Bmc Infectious Diseases,2014,14 ( 8 ) : I - 8.
5曲晓宇,张四喜,闫荟羽,宋燕青.替加环素治疗感染性疾病安全性的Meta分析[J].药物流行病学杂志,2015,24(3):142-147. 被引量：5

二级参考文献39

1颜虹.医学统计学[M].第2版.北京:人民卫生出版社.2010:239-244.
2Stein GE, Babinchak T. Tigecycline: an update [ J ]. Diagn Microbiol Infect Dis,2013,75 (4) :331-336.
3Noskin GA. Tigecycline: A New Glycylcycline for Treatment of Serious Infections[ J ]. Clin Infect Dis ,2005,41 (Suppl 5 ) : S303-314.
4Stein GE, Craig WA. Tigeeycline: A Critical Analysis [ J ]. Clin Infect D/s,2006,43(4) : 518-524.
5Paehon-Ibanez ME, Jimenez-Mejias ME, Piehardo C, et al. Activity of Tigecycline (GAR-936) against Aeinetobacter baumannii Strains, Including Those Resistant to Imipenem [ J ]. Antimicrob Agents Chemother ,2004,48 (.11 ) :4479-4481.
6Sader HS, Jones RN, Dowzicky M J, et al. Antimicrobial ac- tivity of tigecycline tested against nosocomial bacterial patho- gens from patients hospitalized in the intensive care unit [ J ]. Diagn Microbiol Infect Dis ,2005,52 (3) :203-208.
7Karageorgopoulos DE, Kelesidis T, Kelesidis I, et al. Tige- cycline for the treatment of multidrug-resistant ( including car- bapenem-resistant) Acinetobacter infections: a review of the scientific evidence [ J ]. J Antimicrob Chemother, 2008, 62 ( 1 ) :45-55.
8Bassetti M, Nicolini L, Repetto E, et al. Tigeeycline use in serious nosocomial infections: a drug use evaluation [ J ]. BMC Infect D/s,2010,10:287-230.
9US Food and Drug Administration. FDA drug safety communi- cation: increased risk of death with Tygacil (Tigecycline) compared to other antibiotics used to treat similar infections ( Sept 1, 2010) [ EB/OL ]. http://wu , fda. gov/drugs/ Drugsafety/ucm224370. htm, 2011-04- 18/2014-01-01.
10Jadad, AR, Moore RA, Carroll D, et al. Assessing the qual- ity of report of randomized clinical trials: is blinding necessa- ry? [J]. Control Clin Tr/a/s.1996.17(1) :1-12.